PT-141

PT-141 is presented here as a laboratory catalogue entry for research environments that need clear identification, labelled variants, and direct access to supporting records. The current listing includes 1 labelled variant: 10mg. That structure keeps the page useful as both a procurement reference and an indexable resource covering stock visibility, pricing context, and documentation.

Within the wider Au Peptide Labs catalogue, PT-141 sits alongside Tesamorelin, Retatrutide, and Ipamorelin. Researchers often review neighbouring compounds before selecting a comparator or deciding which sequence belongs in a screening panel. Keeping those internal paths close to the product page improves traceability and helps laboratory buyers compare materials without relying on vague or consumer-style copy.

In research literature, PT-141 is generally treated as a melanocortin receptor analog studied in MC receptor subtype-selectivity and downstream signalling assays. The melanocortin receptor family comprises five subtypes (MC1R–MC5R), all class A GPCRs primarily coupling via Gs to adenylyl cyclase. Melanotan I (afamelanotide) is a 13-amino acid [Nle⁴,D-Phe⁷]-α-MSH analog with preferential MC1R selectivity in binding assays. Melanotan II is a cyclic α-MSH analog (Ac-Nle⁴-c[Asp⁵,D-Phe⁷,Lys¹⁰]-α-MSH) with broader selectivity across MC1R, MC3R, MC4R, and MC5R. PT-141 (bremelanotide) is a metabolite of MT-II lacking the N-terminal acetyl and C-terminal amide, which preserves MC3R and MC4R agonism relevant to CNS-focused neuroendocrine assay models while reducing some peripheral receptor activity versus its parent compound.

The five MCR subtypes show distinct tissue distributions and ligand preferences, making receptor-subtype selectivity a central question when designing assay panels. Comparing MT-I, MT-II, and PT-141 in parallel using subtype-selective antagonists (e.g., SHU-9119 at MC3/4R, AGRP at MC3/4R) allows attribution of cAMP responses to individual receptor populations. For laboratory teams, the practical emphasis is usually on sequence identity, receptor or pathway relevance where documented, and whether PT-141 behaves consistently across stability, purity, and analytical verification workflows. Variant labels on this page support clearer internal referencing when multiple labelled variants are under review.

If a product-specific file is not attached to this listing, the wider COA library remains the correct reference point for current published documentation. The COA section is useful for confirming how the product is labelled in the catalogue, whether purity information has been published, and whether the laboratory record for the material is complete before bench use.

When teams compare PT-141 with Tesamorelin, Retatrutide, and Ipamorelin, COA access also helps keep comparator decisions grounded in documented material identity rather than assumption. That is especially important for research pages that combine pricing, variant selection, and analytical records on a single URL.